Quick Facts: Therapeutic Uses

• Chronic Obstructive Pulmonary Disease (COPD): Used as a maintenance treatment to help manage airway obstruction and reduce the frequency of exacerbations.
• Asthma: An option for the long-term, routine management of asthma symptoms in adults and pediatric patients.
• Inflammatory Bowel Disease (IBD): Approved to help induce remission in active, mild-to-moderate Crohn's disease that affects the ileum and/or ascending colon.
• Ulcerative Colitis (UC): Used to help initiate remission in patients with active, mild-to-moderate UC.

Budesonide is an established medication used to address conditions characterized by inflammation, primarily focusing on the respiratory and gastrointestinal systems. For respiratory health, the inhaled formulations are employed for the management of persistent asthma and to help reduce the worsening of COPD symptoms.

In the gastrointestinal tract, various formulations are intended to assist in the control of inflammatory bowel diseases. This includes helping to manage the active phase of mild-to-moderate Crohn's disease. Furthermore, it serves as a therapeutic option to help induce remission in adult patients experiencing active, mild-to-moderate ulcerative colitis. The drug is also used to address chronic inflammation associated with primary immunoglobulin A (IgA) nephropathy, with the goal of reducing protein levels in the urine.

Regulatory References

1. NIH MedlinePlus guidance on Budesonide

Who can and cannot use Budesonide?

The official eligibility for Budesonide (Будесонид) is determined by age, pre-existing health conditions, and the specific formulation being used, as defined in regulatory labeling.

---

Contraindications and Prohibitions

Budesonide is contraindicated (must not be used) in patients with a known hypersensitivity to the drug or any of its components. Inhaled formulations are prohibited for the treatment of acute bronchospasm or status asthmaticus, as they are only indicated for chronic maintenance. Use is also restricted in patients with untreated or inadequately managed systemic infectious conditions, such as active tuberculosis or severe infectious colitis.

Age and Condition-Based Restrictions

Eligibility is highly age-dependent. Inhaled forms for asthma may be approved for pediatric patients as young as 12 months, while oral forms for Crohn's disease are typically limited to children ge 8 years old and adults. The drug is not recommended for patients with moderate to severe hepatic impairment due to the risk of increased systemic exposure. Use during pregnancy and lactation requires a strict assessment, permitted only when the potential benefit outweighs the potential risk.

Interactions with other medicines and products

Pharmacokinetic Interactions

Budesonide is primarily cleared from the body via metabolism by the Cytochrome P450 (CYP) isoenzyme 3A4 system. Interactions are classified as pharmacokinetic and occur when co-administered substances interfere with this metabolic pathway, altering the systemic exposure of Budesonide.

Interaction Type	Interacting Substances/Examples	Documented Outcome
Potent CYP3A4 Inhibitors	Ketoconazole, Itraconazole, Ritonavir, Erythromycin	Significantly increases Budesonide plasma concentration (e.g., up to eight-fold increase with ketoconazole), raising the potential for hypercorticism.
CYP3A4 Inducers	Carbamazepine	Can decrease Budesonide plasma concentration.
Pharmacodynamic	Potassium-lowering Diuretics, Cardiac Glycosides	Increased risk due to Budesonide potentially reducing serum potassium.

Restrictions and Special Considerations

Food and Substance Interactions: The consumption of grapefruit or grapefruit juice must be avoided during treatment with oral Budesonide formulations. Grapefruit juice inhibits CYP3A4 activity in the gut, which can approximately double the systemic exposure of the drug.

Population-Specific Notes: Patients with reduced liver function, such as those with liver cirrhosis, have increased systemic availability of Budesonide due to impaired clearance. For certain oral formulations, use is officially advised to be avoided in cases of severe hepatic impairment (Child-Pugh Class C).

How Budesonide Works

Primary Target: Glucocorticoid Receptor Binding

Budesonide is a synthetic glucocorticoid that initiates its action by penetrating target cells, such as inflammatory cells, and binding with high affinity to the intracellular glucocorticoid receptor (GR). This drug-receptor interaction activates a molecular complex that translocates from the cytoplasm into the cell's nucleus, which precedes the modulation of subsequent genetic expression.

Genomic Modulation: Repressing Inflammatory Genes

Once in the nucleus, the budesonide-GR complex primarily modulates gene activity through transrepression. It interferes with and inhibits the activity of key pro-inflammatory transcription factors, such as NF-kappa B. This action blocks the synthesis of messenger RNA for inflammatory mediators, including specific cytokines and chemokines. The result is the suppression of inflammatory mediator synthesis.

Targeted Activity: Local Receptor Affinity and Systemic Clearance

The molecule is characterized by high local receptor affinity in the target tissue (e.g., airways or gut lining). After any amount is absorbed into the bloodstream, it undergoes rapid and extensive inactivation via high first-pass metabolism in the liver. This mechanistic property results in a high concentration of the active drug at the site of administration, followed by rapid metabolism upon systemic absorption.

Budesonide is an anti-inflammatory corticosteroid that is administered in various formulations, including oral capsules, nasal spray, and inhalation powder or suspension, depending on the condition being treated. Adhere strictly to the dosing schedule and instructions provided by your healthcare provider and the patient information leaflet.

Administration Guidelines by Formulation

Formulation	Key Instructions
Oral Capsules/Tablets	Swallow whole; do not chew, crush, or open extended-release forms. Take them in the morning. Avoid consumption of grapefruit and grapefruit juice as this can increase drug exposure and potential side effects.
Oral Inhalation (Powder/Suspension)	This is for oral inhalation only; use the device (inhaler or nebulizer) as demonstrated by a healthcare professional. To help prevent oral infections (thrush), rinse your mouth with water and spit it out immediately after each use, ensuring you do not swallow the water.
Nasal Spray	Shake the bottle gently before use. Prime the spray mechanism if it is new or has not been used for several days. Blow your nose gently before administration. Insert the tip into the nostril, pointing it toward the side (away from the nasal septum), and spray while sniffing gently. Do not use for longer than directed without consulting a doctor.

General Use Precautions

• Use this medication regularly, even if symptoms improve, to receive the full therapeutic benefit. Do not suddenly stop taking budesonide without medical advice, as this can lead to the return or worsening of symptoms.
• If you miss a dose, take it as soon as you remember unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and resume your regular schedule; do not double the dose.

Research evidence / Overview of Studies for Budesonide

This overview describes the types of clinical research that have been conducted on Budesonide, what has been examined in those studies, and what questions about the evidence remain areas of ongoing research, according to regulatory and scientific bodies. The text avoids providing any clinical advice or individual treatment recommendations.

---

Evidence for Inhaled Use in Asthma and COPD

Research exploring the use of inhaled Budesonide was conducted in the context of persistent asthma through numerous Randomized Controlled Trials (RCTs). Study populations included both adults and pediatric patients with asthma characterized as mild to moderately severe. These trials monitored outcomes related to episodic or acute changes, including the measured frequency of severe asthma flares and changes in lung function measurements. Studies monitored outcomes related to episodic or acute changes, including the measured frequency of severe asthma exacerbations over defined time intervals. For Chronic Obstructive Pulmonary Disease (COPD), research examined the agent, often as one component within a combination inhaler, in studies conducted during periods of increased symptom activity in patients with moderate-to-severe disease. Research examined exacerbation events, with studies monitoring differences in the annual count of these outcomes between the combination and non-corticosteroid arms.

---

Evidence for Targeted Use in Inflammatory Bowel Disease (IBD)

Oral and rectal forms of Budesonide were evaluated in trials for mild-to-moderate Crohn's disease and Ulcerative Colitis. Controlled clinical trials were conducted during periods of increased symptom activity, primarily to study whether the agent was associated with the achievement of clinical remission. The study populations included adults and children with active disease, with trials for Crohn's examining inflammation restricted to the ileum and/or ascending colon. Studies report patterns of symptom development in the observed populations over short-term induction periods (usually 8 to 12 weeks), with findings indicating patterns related to the achievement of remission based on validated scoring systems. However, the evidence is limited to the specified disease location for Crohn's disease, and follow-up durations were limited in many studies.

---

What is Still Uncertain About Budesonide Research

A primary gap is the need for more data concerning the long-term outcomes of continuous use, as follow-up durations were limited in many initial studies. For inhaled use, comparative evidence is lacking in certain contexts, as much of the data for COPD is derived from studies using the medicine as part of a combination product, making it difficult to isolate findings to the single agent. Furthermore, subgroup findings are uncertain for certain comorbidity-defined groups, meaning data for those specific patients remain insufficient. The available research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease

Common questions about Будесонид (FAQ)

---

Q: Will this medication make me feel sleepy or dizzy?

Studies and official information indicate that this medication can cause drowsiness (or similar effects like somnolence or sedation) and dizziness as reported side effects. Because of these potential effects, caution is advised when engaging in activities that require full mental alertness.

Q: What should I do if I miss a dose?

Regulatory documents provide instructions for managing a missed dose. The typical instruction is to take the dose as soon as you remember. However, if it is already close to the time for your next scheduled dose, the typical instruction is to skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed dose.

Q: Can I take this medication if I'm pregnant or breastfeeding?

According to the official product information, the use of this medication is generally not recommended during pregnancy or while breastfeeding. Its use in these situations is generally reserved for cases where a healthcare professional determines that the potential benefits clearly outweigh the possible risks to the baby. Specific warnings may be provided depending on the stage of pregnancy.

Q: Is it safe to drink alcohol while taking this?

Regulatory labelling advises avoiding alcohol or restricting its consumption during treatment. This caution is typically due to the potential for increased central nervous system side effects, such as heightened sedation or drowsiness, when combined with this medication.

Q: What kind of common side effects should I expect?

The regulatory documents list common or frequent side effects. These may include, but are not limited to, reactions such as headache, nausea, and fatigue. Patients are typically directed to consult the full official product information for a comprehensive list of all reported side effects.

Q: Can children 2 years old use it?

Official information indicates that the drug is only authorized for use in children at or above the minimum age specified on the label. Use in children younger than the labelled age is not indicated or approved by regulatory bodies, and official information does not support its use if that age is below the labelled minimum.

Q: Does this medication interact with any vitamins or supplements?

The official product labelling lists specific interactions, which may include certain prescription drugs, as well as specific non-prescription products or herbal/dietary supplements. These interactions are listed because they may either increase the effect of the drug or the risk of side effects, and caution is often advised.

Q: How should I store the medication?

Regulatory documents contain explicit storage instructions to maintain the medication's effectiveness and safety. The product should typically be stored at room temperature, often specified within a range like 20 C to 25 C (68 F to 77 F). It should also be kept away from excessive heat, moisture, and light, unless otherwise specified (e.g., refrigeration).

How to Store and Dispose of Budesonide

All forms of Budesonide must be kept out of the sight and reach of children. The medicine should be stored at Controlled Room Temperature (20 C to 25 C). The label mandates that Budesonide inhalation suspension and nasal spray must not be frozen and should be kept away from excessive heat, light, and moisture.

Packaging and Stability

Keep the medicine in its original container, as required for protection and stability. For the inhalation suspension, once the foil pouch is opened, any unused ampules must be discarded after 2 weeks. Nasal spray bottles must be discarded after the labeled number of sprays has been used.

Disposal Instructions

Unused or expired Budesonide should not be saved. Official regulatory guidelines recommend utilizing a drug take-back program. If one is unavailable, dispose of the medicine by mixing it with an undesirable substance (like coffee grounds) in a sealed bag before placing it in the household trash, then scratch out all personal information on the original packaging.